Predictive Value of FHIT, P27, and PERK1/ERK2 in Salivary Gland Carcinomas: a Retrospective Study

Overview

Journal Clin Oral Investig

Specialty Dentistry

Date 2019 Jan 24

PMID 30673867

Authors

Mathias Fiedler

Patty Renner

Jurgen Schubert

Florian Weber

Arndt Hartmann

Heinrich Iro

Veronika Vielsmeier

Christopher Bohr

Michael Gerken

Torsten E Reichert

Tobias Ettl

Affiliations

Soon will be listed here.

Abstract

Objectives: The aim of this study was to investigate the predictive value of the biomarkers FHIT, p27, and pERK1/ERK2 in salivary gland carcinomas.

Material And Methods: Immunohistochemical staining of FHIT, p27, and pERK1/ERK2 of 265 patients with salivary gland carcinomas was conducted, and associations with clinico-histopathological data, overall survival, and disease-specific survival were examined.

Results: Expression of FHIT (quick score 98.7 vs. 206.4) and p27 (QS 187.3 vs. 244.8) was significantly lower in carcinomas compared to non-tumor control tissue. Loss of FHIT frequently occurred in ACC (55.2%), SDC (68.2%), and SCC (100%). In the totality of tumors, loss of FHIT expression was found in 46.7% (106/227) and was significantly associated with advanced T stage and UICC stage, high-grade histology, loss of p27, PI3K, and survivin. FHIT positivity went along with significantly better overall and disease-specific survival. Negativity of p27 occurred in 28.7% (70/244) of tumors, particularly in SDC (54.4%) and SCC (50%). In the totality of tumors, p27 was associated with advanced patient age, high-grade histology, PI3K, survivin as well as better overall and disease-specific survival (p < 0.05). Positive pERK1/ERK2 expression correlated with positive survivin expression but did not affect overall survival in the totality of tumors. In mucoepidermoid carcinomas, pERK1/ERK2 expression was associated with low-grade malignancy, positive nuclear survivin, and better disease-specific survival.

Conclusions: Loss of FHIT and p27 characterizes aggressive tumor growth and unfavorable prognosis in salivary gland cancer.

Clinical Relevance: The results may help to stratify patient-specific therapies according to individual tumor characteristics.

References

Chen X, Duan N, Zhang C, Zhang W . Survivin and Tumorigenesis: Molecular Mechanisms and Therapeutic Strategies. J Cancer. 2016; 7(3):314-23. PMC: 4747886. DOI: 10.7150/jca.13332. View

Handra-Luca A, Bilal H, Bertrand J, Fouret P . Extra-cellular signal-regulated ERK-1/ERK-2 pathway activation in human salivary gland mucoepidermoid carcinoma: association to aggressive tumor behavior and tumor cell proliferation. Am J Pathol. 2003; 163(3):957-67. PMC: 1868241. DOI: 10.1016/S0002-9440(10)63455-4. View

El-Naggar A . What Is New in the World Health Organization 2017 Histopathology Classification?. Curr Treat Options Oncol. 2017; 18(7):43. DOI: 10.1007/s11864-017-0469-x. View

Milanes-Yearsley M, Hammond M, Pajak T, Cooper J, Chang C, Griffin T . Tissue micro-array: a cost and time-effective method for correlative studies by regional and national cancer study groups. Mod Pathol. 2002; 15(12):1366-73. DOI: 10.1097/01.MP.0000036345.18944.22. View

Milde-Langosch K, Bamberger A, Rieck G, Grund D, Hemminger G, Muller V . Expression and prognostic relevance of activated extracellular-regulated kinases (ERK1/2) in breast cancer. Br J Cancer. 2005; 92(12):2206-15. PMC: 2361826. DOI: 10.1038/sj.bjc.6602655. View

Speight P, Barrett A . Salivary gland tumours. Oral Dis. 2002; 8(5):229-40. DOI: 10.1034/j.1601-0825.2002.02870.x. View

Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet J, Lecomte T . Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol. 2009; 27(35):5924-30. DOI: 10.1200/JCO.2008.21.6796. View

Ettl T, Schwarz-Furlan S, Haubner F, Muller S, Zenk J, Gosau M . The PI3K/AKT/mTOR signalling pathway is active in salivary gland cancer and implies different functions and prognoses depending on cell localisation. Oral Oncol. 2012; 48(9):822-30. DOI: 10.1016/j.oraloncology.2012.02.021. View

Dincer N, Guler Tezel G, Sungur A, Himmetoglu C, Huebner K, Guler G . Study of FHIT and WWOX expression in mucoepidermoid carcinoma and adenoid cystic carcinoma of salivary gland. Oral Oncol. 2010; 46(3):195-9. DOI: 10.1016/j.oraloncology.2009.12.003. View

10.

Donovan J, Milic A, Slingerland J . Constitutive MEK/MAPK activation leads to p27(Kip1) deregulation and antiestrogen resistance in human breast cancer cells. J Biol Chem. 2001; 276(44):40888-95. DOI: 10.1074/jbc.M106448200. View

11.

Zhao P, Meng Q, Liu L, You Y, Liu N, Jiang B . Regulation of survivin by PI3K/Akt/p70S6K1 pathway. Biochem Biophys Res Commun. 2010; 395(2):219-24. DOI: 10.1016/j.bbrc.2010.03.165. View

12.

Handra-Luca A, Ruhin B, Lesty C, Fouret P . P27, SKP2, and extra-cellular signal-related kinase signalling in human salivary gland mucoepidermoid carcinoma. Oral Oncol. 2006; 42(10):1005-10. DOI: 10.1016/j.oraloncology.2005.12.022. View

13.

Lujan B, Hakim S, Moyano S, Nadal A, Caballero M, Diaz A . Activation of the EGFR/ERK pathway in high-grade mucoepidermoid carcinomas of the salivary glands. Br J Cancer. 2010; 103(4):510-6. PMC: 2939786. DOI: 10.1038/sj.bjc.6605788. View

14.

Dumon K, Ishii H, Vecchione A, Trapasso F, Baldassarre G, Chakrani F . Fragile histidine triad expression delays tumor development and induces apoptosis in human pancreatic cancer. Cancer Res. 2001; 61(12):4827-36. View

15.

Sarli L, Bottarelli L, Azzoni C, Campanini N, Di Cola G, Barilli A . Loss of p27 expression and microsatellite instability in sporadic colorectal cancer. Surg Oncol. 2006; 15(2):97-106. DOI: 10.1016/j.suronc.2006.09.002. View

16.

Cao J, Li W, Xie J, Du H, Tang W, Wang H . Down-regulation of FHIT inhibits apoptosis of colorectal cancer: mechanism and clinical implication. Surg Oncol. 2007; 15(4):223-33. DOI: 10.1016/j.suronc.2007.01.006. View

17.

Ettl T, Stiegler C, Zeitler K, Agaimy A, Zenk J, Reichert T . EGFR, HER2, survivin, and loss of pSTAT3 characterize high-grade malignancy in salivary gland cancer with impact on prognosis. Hum Pathol. 2011; 43(6):921-31. DOI: 10.1016/j.humpath.2011.08.006. View

18.

Ettl T, Baader K, Stiegler C, Muller M, Agaimy A, Zenk J . Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer. Br J Cancer. 2012; 106(4):719-26. PMC: 3282188. DOI: 10.1038/bjc.2011.605. View

19.

Deschenes-Simard X, Kottakis F, Meloche S, Ferbeyre G . ERKs in cancer: friends or foes?. Cancer Res. 2014; 74(2):412-9. DOI: 10.1158/0008-5472.CAN-13-2381. View

20.

Ach T, Zeitler K, Schwarz-Furlan S, Baader K, Agaimy A, Rohrmeier C . Aberrations of MET are associated with copy number gain of EGFR and loss of PTEN and predict poor outcome in patients with salivary gland cancer. Virchows Arch. 2012; 462(1):65-72. DOI: 10.1007/s00428-012-1358-0. View